10-K: Sonoma Pharmaceuticals Reports FY26 Results, Revenue Up 37%

Sonoma Pharmaceuticals, Inc. announced its fiscal year 2026 results, highlighting a 37% increase in total revenue to $19.5 million, driven by strong performance in the United States and international markets.

Summary

• Sonoma Pharmaceuticals reported total revenues of $19.5 million for the fiscal year ended March 31, 2026, a 37% increase from $14.3 million in the prior year.
• The United States market saw significant growth, with revenues increasing by 117% to $5.7 million, attributed to increased sales of over-the-counter products and expanded distribution.
• International markets also contributed positively, with Europe up 25% to $6.9 million, Asia up 25% to $2.9 million, and Rest of World up 92% to $1.7 million.
• Latin America experienced a 20% decrease in revenue to $2.4 million, primarily due to the timing of customer orders for overflow manufacturing.
• Gross profit increased by 36% to $7.4 million, maintaining a gross profit margin of 38%, consistent with the previous year.
• Research and development expenses rose by 25% to $2.3 million, supporting new product releases.
• Selling, general, and administrative expenses increased by 3% to $7.6 million.
• The company reported a net loss of $3.2 million for the fiscal year, an improvement from a net loss of $3.5 million in the prior year.
• Cash and cash equivalents decreased to $2.4 million as of March 31, 2026, from $5.4 million in the prior year, with net cash used in operating activities at $3.9 million.
• The company raised $427,000 through the sale of common stock and received $374,000 from employee retention credits during the fiscal year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with strong revenue growth and strategic product launches indicating positive momentum, offset by continued net losses and a decrease in cash reserves.

Positives

• Total revenue increased by 37% to $19.5 million for the fiscal year ended March 31, 2026.
• Significant revenue growth in the United States, up 117% to $5.7 million.
• Strong revenue growth in Europe (25%), Asia (25%), and Rest of World (92%).
• Gross profit increased by 36% to $7.4 million, with a stable gross margin of 38%.
• Net loss decreased to $3.2 million from $3.5 million in the prior year.
• Successful transition to the new EU Medical Devices Regulation (MDR) for all commercialized products in Europe.
• Received National Psoriasis Foundation Seal of Recognition and National Rosacea Society Seal of Acceptance for Reliefacyn in August and November 2025, respectively.
• Launched advanced HOCl-based burn relief hydrogel in CVS and Walmart stores in March 2026.
• Launched Aquanil AD, a new dermatology product line for sensitive skin, in March 2026.
• Registered manufacturing facility and listed Microcyn-based facial spray under FDA's MoCRA in October 2025.
• Launched new HOCl wound cleanser for Medline Industries in October 2025.
• Expanded partnership with a U.S.-based distributor for Microcyn technology-based products in July 2025.
• Launched HOCl-based acne products in over 1,200 stores in the UK in April 2025.
• Received regulatory approval for wound care products in Ukraine in April 2025.
• Entered into a five-year distribution agreement with Medline Industries, LP for wound care products in the U.S. in August 2024, amended in October 2024 to include Canada and retail sales.

Negatives

• Net loss of $3.2 million for the fiscal year ended March 31, 2026.
• Accumulated deficit stands at $201.0 million as of March 31, 2026.
• Cash and cash equivalents decreased to $2.4 million from $5.4 million.
• Net cash used in operating activities was $3.9 million for the fiscal year.
• Latin America revenues decreased by 20% to $2.4 million.
• Significant intercompany debt and accrued interest owed by the Mexico subsidiary ($12.3 million principal, $10.4 million technical assistance, $32.2 million interest) due in 2032.
• Potential Mexico income tax liability of approximately $16.5 million if debt is forgiven or converted to equity.
• Potential Mexico withholding tax of approximately $5.6 million if intercompany interest and technical assistance are repaid.
• The company has not been able to deduct intercompany interest on its Mexico tax returns since 2004 due to thin capitalization rules.
• The company is prevented from claiming foreign tax credits on its U.S. income tax return due to substantial U.S. net operating losses.

Risks

• Dependence on third-party distributors and potential delays or failures in commercializing products if collaborations are unsuccessful.
• The Mexico subsidiary owes substantial amounts in principal, technical assistance, and accrued interest, with no guarantee of repayment.
• Potential tax liabilities in Mexico if intercompany debt is forgiven or converted to equity.
• Inability to deduct intercompany interest in Mexico due to thin capitalization rules, preventing the accrual of net operating losses.
• Reliance on a few key customers for a significant portion of revenues, with the risk of revenue decline if any are lost.
• Exposure to international risks including political or economic instability, exchange rate fluctuations, changes in regulations, trade restrictions, and difficulties in managing foreign operations.
• Failure to obtain or significant delays in obtaining additional regulatory clearances or approvals for current or future products.
• Potential for product recalls or market withdrawal if ongoing regulatory requirements are not met or if unanticipated problems arise.
• Risk of manufacturing difficulties that could prevent commercialization of products.
• Inability to protect intellectual property and proprietary technologies adequately.
• Exposure to foreign currency exchange rate fluctuations impacting revenues and potentially demand for products.
• Intense competition from larger companies with greater financial resources and expertise.
• Potential failure to establish successful collaborative or license arrangements for product development and commercialization.
• Substantial penalties and exclusion from government healthcare programs if fraud and abuse laws are violated.
• Inability to raise additional capital on acceptable terms in the future, potentially curtailing operational activities.
• Vulnerability to cybersecurity breaches that could lead to liability, reputational damage, or compromise of confidential information.
• Market price volatility of common stock and potential for significant decline in investment value.
• Fluctuations in operating results that could cause stock price decreases.
• Anti-takeover provisions in corporate documents and Delaware law that may make management changes or takeovers difficult.
• Potential for substantial dilution to stockholders if additional shares are issued.
• Risk of delisting from Nasdaq if continued listing requirements are not met.

Future Outlook

Management believes that the Company's existing cash, proceeds from the recent Dawson offering, and expected cash flow management will be sufficient to fund its projected operating requirements for at least the next twelve months. The company also has access to additional capital resources through public or private equity offerings, debt financings, or corporate collaborations, if and when appropriate. However, there is no assurance that such financings will be available on commercially acceptable terms.

Management Comments

• We have continued our focus on increasing revenues and continuing progress towards profitability.
• During our most recent fiscal year, our revenues have grown as a result of continued expansion of our distribution network and customer base including increasing expansion into consumer markets, the introduction of new products into multiple markets around the world, as well as organic growth from existing customers and distributors.
• We have also focused on expanding and strengthening our regulatory reach by seeking new approvals and clearances.

Industry Context

StockSavvy.ai notes that Sonoma Pharmaceuticals operates in the competitive healthcare sector, focusing on stabilized hypochlorous acid (HOCl) products. The company's strategy of expanding its distribution network, introducing new products, and seeking regulatory approvals aligns with industry trends towards specialized and effective therapeutic solutions. The reported revenue growth indicates successful market penetration, though continued investment in R&D and navigating complex regulatory landscapes remain critical.

Comparison to Industry Standards

• The company's gross profit margin of 38% is within the typical range for specialty chemical and medical device manufacturers, though direct comparison is difficult without specific product category benchmarks.
• Research and development expenses as a percentage of revenue (12% for FY26) are consistent with or slightly higher than many pharmaceutical and medical device companies, reflecting a commitment to innovation in its HOCl technology.
• The company's international revenue contribution (approximately 71% in FY26) is substantial, indicating a global market presence that is common among successful healthcare product companies, though it also exposes the company to greater geopolitical and currency risks compared to purely domestic players.
• The company's focus on regulatory approvals (FDA clearances, CE marking) is standard practice for medical device companies, but the ongoing transition to new regulations like the EU MDR presents challenges faced by many in the industry.

Corporate Governance

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology. Management believes these matters are currently insignificant, but they could have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• The company has loaned substantial amounts to its Mexico subsidiary, Oculus Technologies of Mexico, S.A. de C.V., which as of March 31, 2026, owed approximately $12.3 million in principal, $10.4 million in technical assistance payments, and $32.2 million in accrued interest. These intercompany loans mature in 2032.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, but also potential upside from revenue growth and new product launches. Volatility in stock price is noted.
• Employees: Continued focus on growth and profitability may lead to job security and potential for stock-based compensation. The company has 9 employees in the US, 1 in the Netherlands, and approximately 250 in Mexico.
• Customers: Access to innovative HOCl-based products for wound care, dermatology, eye care, and animal health. Expansion into retail channels (CVS, Walmart) increases accessibility.
• Suppliers: Continued demand for raw materials and components for manufacturing.
• Creditors: The company has short-term debt of $222,000 related to insurance premium financing. The company's liquidity and ability to meet future obligations are supported by recent capital raises.

Next Steps

• Continue to focus on increasing revenues and progressing towards profitability.
• Continue to expand the distribution network and customer base.
• Introduce new products into multiple markets.
• Seek new regulatory approvals and clearances to expand potential markets.
• Invest in research and development for core HOCl technology.
• Manage intercompany debt and tax liabilities with the Mexico subsidiary.
• Monitor global economic conditions and their potential impact on financial results.

Key Dates

Recommendation

Sonoma Pharmaceuticals shows promising revenue growth and strategic product expansions, particularly in the US market. However, the continued net losses, decreasing cash reserves, and significant intercompany debt with potential tax implications in Mexico warrant caution. While the recent capital raise provides a buffer, the path to profitability remains uncertain. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained profitability and resolution of financial risks.

Keywords

Sonoma Pharmaceuticals, 10-K, Annual Report, Hypochlorous Acid, HOCl, Wound Care, Dermatology, Eye Care, Animal Health, Disinfectant, Revenue Growth, Net Loss, Financial Results, SEC Filing, SNOA